EUVIMEDEUVIMED entdecken
Open Access

Moving Beyond Mortality: Development and Application of a Desirability of Outcome Ranking (DOOR) Endpoint for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia

Jessica Howard-Anderson iD, Toshimitsu Hamasaki, Weixiao Dai, Deborah Collyar, Daniel Rubin, Sumathi Nambiar, Tori Kinamon, Heidi Leister-Tebbe, Carol Hill, Holly Geres, Thomas L Holland, Sarah B Doernberg und 5 weitere

Clinical Infectious Diseases · 17.02.2024 · 78 (2) · 259-268

DOI: 10.1093/cid/ciad576 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 22.09.2023. Verfasst von Jessica Howard-Anderson und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Pneumonia, Bacterial, Healthcare-Associated Pneumonia, Pneumonia, Ventilator-Associated. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIH HHS, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) are frequently caused by multidrug-resistant organisms. Patient-centered endpoints in clinical trials are needed to develop new antibiotics for HABP/VABP. Desirability of outcome ranking (DOOR) is a paradigm for the design, analysis, and interpretation of clinical trials based on a patient-centered, benefit-risk evaluation.

Methods

A multidisciplinary committee created an infectious diseases DOOR endpoint customized for HABP/VABP, incorporating infectious complications, serious adverse events, and mortality. We applied this to 2 previously completed, large randomized controlled trials for HABP/VABP. ZEPHyR compared vancomycin to linezolid and VITAL compared linezolid to tedizolid. For each trial, we evaluated the DOOR distribution and probability, including DOOR component and partial credit analyses. We also applied DOOR in subgroup analyses.

Results

In both trials, the HABP/VABP DOOR demonstrated similar overall clinical outcomes between treatment groups. In ZEPHyR, the probability that a participant treated with linezolid would have a more desirable outcome than a participant treated with vancomycin was 50.2% (95% confidence interval [CI], 45.1%­−55.3%). In VITAL, the probability that a participant treated with tedizolid would have a more desirable outcome than a participant treated with linezolid was 48.7% (95% CI, 44.8%–52.6%). The DOOR component analysis revealed that participants treated with tedizolid had a less desirable outcome than those treated with linezolid when considering clinical response alone. However, participants with decreased renal function had improved overall outcomes with tedizolid.

Conclusions

The HABP/VABP DOOR provided more granular information about clinical outcomes than is typically presented in clinical trials. HABP/VABP trials would benefit from prospectively using DOOR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pneumonia, BacterialHealthcare-Associated PneumoniaPneumonia, Ventilator-AssociatedHumansLinezolidVancomycinAnti-Bacterial AgentsBacteriaHospitalsVentilators, Mechanical

Stichwörter der Autor:innen

clinical trialsdesirability of outcome rankingdrug developmenthospital-acquired bacterial pneumoniaventilator-associated bacterial pneumonia

Substanzen

LinezolidVancomycinAnti-Bacterial Agents

Autor:innen und Institutionen

  • Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Biostatistics Center and Department of Biostatistics and Bioinformatics, Milken Institute School of Public Health, The George Washington University, Washington, District of Columbia, USA.
  • Patient Advocates in Research, Danville, California, USA.
  • Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
  • Johnson and Johnson, Raritan, New Jersey, USA.
  • Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.

ORCID-Profile: Jessica Howard-Anderson

Förderung

  • NIAID NIH HHS
  • NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • National Institutes of Health
  • US Food and Drug Administration
  • Oak Ridge Institute for Science and Education
  • US Department of Energy
  • Antibacterial Research Leadership Group

Zitieren

APA

Howard-Anderson, J., Hamasaki, T., Dai, W., Collyar, D., Rubin, D., Nambiar, S., Kinamon, T., Leister-Tebbe, H., Hill, C., Geres, H., Holland, T. L., Doernberg, S. B., Chambers, H. F., Fowler, V. G., Evans, S. R., Boucher, H. W., & Antibacterial Resistance Leadership Group (2024). Moving Beyond Mortality: Development and Application of a Desirability of Outcome Ranking (DOOR) Endpoint for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia. Clinical Infectious Diseases, 78(2), 259-268. https://doi.org/10.1093/cid/ciad576

Vancouver

Howard-Anderson J, Hamasaki T, Dai W, Collyar D, Rubin D, Nambiar S, et al. Moving Beyond Mortality: Development and Application of a Desirability of Outcome Ranking (DOOR) Endpoint for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia. Clinical Infectious Diseases. 2024;78(2):259-268. doi:10.1093/cid/ciad576

BibTeX
@article{HowardAnderson2024,
  author = {Howard-Anderson, Jessica and Hamasaki, Toshimitsu and Dai, Weixiao and Collyar, Deborah and Rubin, Daniel and Nambiar, Sumathi and Kinamon, Tori and Leister-Tebbe, Heidi and Hill, Carol and Geres, Holly and Holland, Thomas L and Doernberg, Sarah B and Chambers, Henry F and Fowler, Vance G and Evans, Scott R and Boucher, Helen W and Antibacterial Resistance Leadership Group, Antibacterial Resistance Leadership Group},
  title = {Moving Beyond Mortality: Development and Application of a Desirability of Outcome Ranking (DOOR) Endpoint for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia},
  journal = {Clinical Infectious Diseases},
  year = {2024},
  volume = {78},
  number = {2},
  pages = {259--268},
  doi = {10.1093/cid/ciad576}
}
Kostenlos starten →